Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1905 1
1912 1
1917 1
1923 1
1927 1
1928 1
1931 1
1932 2
1936 3
1937 3
1938 4
1939 4
1940 1
1942 2
1944 1
1945 6
1946 15
1947 15
1948 21
1949 14
1950 31
1951 23
1952 32
1953 43
1954 34
1955 34
1956 35
1957 50
1958 38
1959 43
1960 26
1961 32
1962 49
1963 84
1964 102
1965 72
1966 66
1967 78
1968 83
1969 93
1970 109
1971 119
1972 117
1973 94
1974 108
1975 78
1976 64
1977 95
1978 65
1979 71
1980 77
1981 62
1982 81
1983 92
1984 76
1985 100
1986 106
1987 89
1988 99
1989 110
1990 87
1991 98
1992 98
1993 118
1994 116
1995 119
1996 125
1997 122
1998 138
1999 122
2000 145
2001 142
2002 176
2003 160
2004 160
2005 185
2006 185
2007 176
2008 218
2009 237
2010 230
2011 261
2012 307
2013 276
2014 295
2015 289
2016 370
2017 369
2018 409
2019 414
2020 522
2021 596
2022 625
2023 632
2024 267

Text availability

Article attribute

Article type

Publication date

Search Results

10,848 results

Results by year

Filters applied: . Clear all
Page 1
Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.
Leung AKC, Lam JM, Alobaida S, Leong KF, Wong AHC. Leung AKC, et al. Curr Pediatr Rev. 2021;17(4):273-287. doi: 10.2174/1573396317666210426105045. Curr Pediatr Rev. 2021. PMID: 33902423 Review.
In 2017, the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) developed diagnostic criteria for juvenile idiopathic inflammatory myopathies and juvenile dermatomyositis. In the absence of muscle biopsies which are infr …
In 2017, the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) developed diagnostic criteria for juv …
Dermatomyositis.
O'Connell KA, LaChance AH. O'Connell KA, et al. N Engl J Med. 2021 Jun 24;384(25):2437. doi: 10.1056/NEJMicm2033425. N Engl J Med. 2021. PMID: 34161709 No abstract available.
Juvenile dermatomyositis. Where are we now?
McCann LJ, Livermore P, Wilkinson MGL, Wedderburn LR. McCann LJ, et al. Clin Exp Rheumatol. 2022 Feb;40(2):394-403. doi: 10.55563/clinexprheumatol/56ilob. Epub 2022 Feb 7. Clin Exp Rheumatol. 2022. PMID: 35225221 Free article. Review.
This review will focus on recent developments in understanding and treatment of juvenile dermatomyositis (JDM), the most common disease sub-type of IIM in childhood. ...
This review will focus on recent developments in understanding and treatment of juvenile dermatomyositis (JDM), the most common disea …
Juvenile Dermatomyositis-Clinical Phenotypes.
Li D, Tansley SL. Li D, et al. Curr Rheumatol Rep. 2019 Dec 11;21(12):74. doi: 10.1007/s11926-019-0871-4. Curr Rheumatol Rep. 2019. PMID: 31828535 Free PMC article. Review.
PURPOSE OF REVIEW: Juvenile dermatomyositis is a heterogeneous disease with variable clinical outcomes. ...It is increasingly apparent that autoantibodies can provide detailed information on prognosis and the likely disease associations in those with juvenile dermatomyo …
PURPOSE OF REVIEW: Juvenile dermatomyositis is a heterogeneous disease with variable clinical outcomes. ...It is increasingly apparen …
Current diagnosis and treatment of polymyositis and dermatomyositis.
Sasaki H, Kohsaka H. Sasaki H, et al. Mod Rheumatol. 2018 Nov;28(6):913-921. doi: 10.1080/14397595.2018.1467257. Epub 2018 May 9. Mod Rheumatol. 2018. PMID: 29669460 Review.
Idiopathic inflammatory myopathies (IIMs) are heterogeneous disorders that affect the skeletal muscles. Polymyositis, dermatomyositis, and inclusion body myositis are major IIM subsets. Immune-mediated necrotizing myopathy became recognized as a potentially n …
Idiopathic inflammatory myopathies (IIMs) are heterogeneous disorders that affect the skeletal muscles. Polymyositis, derma …
[Anti-MDA5 dermatomyositis. Literature review].
Castro-Molina SA, Méndez-Flores S. Castro-Molina SA, et al. Rev Med Inst Mex Seguro Soc. 2023 Jan 2;61(1):99-105. Rev Med Inst Mex Seguro Soc. 2023. PMID: 36542793 Free PMC article. Review. Spanish.
Dermatomyositis positive anti-melanoma differentiation-associated gene 5 (anti-MDA5 DM) is a rare disease that represents less than 2%. ...The clinical picture may be variable and is accompanied by the typical features of dermatomyositis, such as periorbital heliotr …
Dermatomyositis positive anti-melanoma differentiation-associated gene 5 (anti-MDA5 DM) is a rare disease that represents less than 2 …
Dermatomyositis.
Chu LL, Rohekar G. Chu LL, et al. CMAJ. 2019 Mar 25;191(12):E340. doi: 10.1503/cmaj.180947. CMAJ. 2019. PMID: 30910882 Free PMC article. No abstract available.
Anti-MDA5 dermatomyositis: an update from bench to bedside.
Fuzzi E, Gatto M, Zen M, Franco C, Zanatta E, Ghirardello A, Doria A. Fuzzi E, et al. Curr Opin Rheumatol. 2022 Nov 1;34(6):365-373. doi: 10.1097/BOR.0000000000000908. Epub 2022 Sep 12. Curr Opin Rheumatol. 2022. PMID: 36094462 Free PMC article. Review.
RECENT FINDINGS: Anti-MDA5+ dermatomyositis has a heterogeneous clinical spectrum with different patient subsets exhibiting widely different outcomes; severe acute interstitial lung disease is the main factor impacting prognosis. The pathogenetic role of anti-MDA5 antibodi …
RECENT FINDINGS: Anti-MDA5+ dermatomyositis has a heterogeneous clinical spectrum with different patient subsets exhibiting widely di …
Paraneoplastic Dermatomyositis.
Orton C, Topham C, Madigan LM. Orton C, et al. Am J Med. 2022 Aug;135(8):969-971. doi: 10.1016/j.amjmed.2022.01.016. Epub 2022 Feb 24. Am J Med. 2022. PMID: 35219689 No abstract available.
JAK-inhibitors for dermatomyositis: A concise literature review.
Paudyal A, Zheng M, Lyu L, Thapa C, Gong S, Yang Y, Lyu X. Paudyal A, et al. Dermatol Ther. 2021 May;34(3):e14939. doi: 10.1111/dth.14939. Epub 2021 Mar 23. Dermatol Ther. 2021. PMID: 33713527 Review.
Refractory dermatomyositis (DM) is defined as cases that do not show improvement after initial treatment with two different immunosuppressives combined with corticosteroids with or without intravenous immunoglobulins. ...
Refractory dermatomyositis (DM) is defined as cases that do not show improvement after initial treatment with two different immunosup …
10,848 results
You have reached the last available page of results. Please see the User Guide for more information.